BCRX BioCryst Pharmaceuticals, Inc.

NASDAQ
$7.30

BioCryst Pharmaceuticals, Inc. (BCRX) is expected to report earnings on February 3, 2027, before the market open. The consensus earnings estimate is $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.4% since its last earnings release on November 4, 2026.

BioCryst Pharmaceuticals Beat Consensus Estimates, Raises Guidance
Wednesday, November 4, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 7:00 AM ET
Earnings Whisper
-
vs $0.11
Rev est $167.62M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.72

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About BioCryst Pharmaceuticals, Inc.

Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.